共查询到19条相似文献,搜索用时 109 毫秒
1.
2.
绝经后骨质疏松症的中西医危险因素调查研究 总被引:3,自引:0,他引:3
依照流行病学病例-对照研究方法,采用条件Logistic回归模型,对泉州地区绝经后妇女进行绝经后骨质疏松症的危险因素水平调查.Logistic分析结果显示,肾虚、血瘀、绝经年限与绝经后骨质疏松症密切正相关,运动时间、E2、E2/T与绝经后骨质疏松症密切负相关.中医指标肾虚和血瘀为绝经后骨质疏松症的独立危险因素,不能被西医指标所取代. 相似文献
3.
妇女绝经后骨质疏松症 总被引:2,自引:2,他引:0
女性绝经后骨质疏松症(postmenopausal Osteoporosis)是指绝经后妇女由卵巢功能衰退,雌激素水平下降,继发甲状旁腺功能亢进,降钙素分泌不足,从而导致骨吸收大于骨形成,出现以低骨量和骨组织的显微结构退行性变为其特征,临床表现为骨性和骨折易感性增加的一种代谢性疾病,骨质疏松症的临床表现大都为非特异性,患者多有腰背和四肢慢性疼痛,骨质丧人骨矿质减少,骨孔多,脆性增加,导致内骼强度下降,极易发生骨折。 相似文献
4.
目的 分析社区绝经后妇女骨质疏松症筛查结果及影响因素,评价亚洲绝经后妇女骨质疏松自我筛查(osteoporosis self-assessment tool for Asians,OSTA)指数评分对绝经后妇女骨质疏松风险的预测能力,为同行开展社区骨质疏松症相关人群识别提供经验借鉴。 方法 以2019年3—4月期间在上海市浦东新区曹路社区卫生服务中心参加骨质疏松筛查的5 191名绝经后妇女为研究对象。采用调查问卷结合跟骨超声骨密度检测进行骨质疏松筛查。采用SPSS 24.0统计学软件进行数据分析。 结果 5 191名绝经后妇女中,1 502人(28.93%)有中级及以上骨质疏松风险,且跟骨超声结果显示,1 280人(24.66%) T值≤-2.0。年龄越大、BMI越小、OSTA评分越低,T值越低(均P<0.05),有无低体重、脆性骨折史、腰背部疼痛、跌倒史、帕金森、子宫及卵巢癌以及骨松风险分级不同,跟骨超声测量出的T值差异有统计学意义(均P<0.05)。OSTA评分是否≤-1,与跟骨超声测出的T值是否≤-2.0,有较差的一致性(Kappa=0.197<0.4,P<0.05)。 结论 社区骨质疏松风险人群的识别,可将OSTA评估、跟骨超声,与BMI或低体重、脆性骨折史、腰背部疼痛、跌倒史、帕金森、子宫及卵巢癌等个人健康并既往病史情况结合使用。 相似文献
5.
6.
目的:探讨维生素D对绝经后妇女骨质疏松症的治疗效果。方法:将40例绝经后骨质疏松症患者,随机分为复方氨基酸螯合钙联合维生素AD治疗组(20例)和葡萄糖酸钙联合性激素对照治疗组(20例)。治疗组在用复方氨基酸敖合钙的同时联合维生素AD,疗程3个月。对照组在用葡萄糖酸钙的同时联合尼尔雌醇,疗程3个月。治疗3个月后分别观察临床症状及X线片、骨密度恢复情况。结果:两组临床症状、X线片、骨密度恢复率分别为95.0%和75.0%。治疗组临床症状、X线片及骨密度恢复率优于治疗组(P<0.005)。结论:复方氨基酸螯合钙联合维生素AD能够提高绝经后妇女骨质疏松症的治疗效果。 相似文献
7.
目的 探讨老年骨质疏松症的相关危险因素.方法 随机选取2009年12月~2010年12月在笔者所在医院保健门诊就诊的离退休老年患者260例,分为骨质疏松组和无骨质疏松组,对其进行骨质疏松症相关危险因素的问卷调查,采用SAS 9.0进行多因素Logistic回归分析.结果 骨质疏松组女性、BMI≥24、饮酒、吸烟、常喝浓茶或咖啡、每天户外活动时间<2 h、患心脑血管疾病和(或)内分泌疾病者所占比例明显高于无骨质疏松组,差异有统计学意义(P<0.05).多因素Logistic回归分析结果显示,女性、患心脑血管疾病和(或)内分泌疾病、不良生活习惯、不良饮食习惯、户外运动量少是老年骨质疏松症的危险因素.结论 老年骨质疏松症是与年龄、性别、文化程度、生活习惯、心脑血管疾病和(或)内分泌疾病等因素密切相关的全身性疾病,进行治疗时应采取系统全身性措施,在给社区居民进行健康教育时应给予全面指导. 相似文献
8.
绝经后骨质疏松症是指骨矿物质和骨基质随妇女绝经后等比例的减少,骨组织的显微结构发生改变,使其骨组织的正常荷载功能发生变化,骨折危险度明显增加,伴有周身骨骼疼痛,体态变形等症的疾病。对绝经后妇女的危害性极大,根据多年的临床观察及治疗护理探讨,对骨质密度减低的绝经后妇女,经常保持心情舒畅,充分补钙,增加户外活动等措施,可减少并发症。 相似文献
9.
目的:探讨绝经后骨质疏松症(PMOP)发病相关危险因素及预防措施.方法:筛选临床确诊为PMOP病人共176例,对所有病人的腰椎和髋骨部位的骨密度进行测量,同时统计所有病人的年龄、体质量、身高、绝经年限、生育情况和运动情况等作为影响因素,使用向后迭代法对影响因素进行考察,以病人骨密度是否减少作为因变量建立定序logistic模型,将通过考察的因素代入模型中进行权重考察,研究各因素对绝经后骨质疏松症发病的相关性,并探讨相关预防措施.结果:最终筛选年龄、体质量、绝经年限、生育情况、饮食习惯、目前运动习惯、年轻时期运动习惯对因变量有显著的解释能力,其中年龄、绝经年限、生育情况与骨质减少情况呈正相关,为发病危险因素,而体质量、饮食情况、目前运动情况和年轻时期运动情况与骨质减少情况呈负相关,是此类疾病的保护因素.结论:改善PMOP病人的饮食结构,适量增加病人体质量和脂肪含量,有效规划病人的日常运动情况能够有效地减慢病人骨密度降低的速度,有效控制PMOP发病率. 相似文献
10.
随着人口老龄化进程的加速,老年人数的增多,原发性骨质疏松症已成为老年人尤其是绝经后妇女的常见病多发病。骨质疏松所致的骨痛及骨折给患者带来的极大痛苦,给社会和家庭造成的沉重经济负担,已引起世界广泛的关注。全世界约四分之一的绝经妇女在中国,而我国有关绝经后骨质疏松的研究起步较晚。因此,提高全社会对这一严重疾病的认识,做好防治,改善老年妇女的生命质量是当务之急。现就所见文献,对这项研究的现状作一介绍。 相似文献
11.
不同剂量雌激素在绝经后骨质疏松症治疗中的作用 总被引:2,自引:0,他引:2
段定红 《复旦学报(医学版)》2003,30(5):477-479
目的 研究不同剂量雌激素对绝经后骨质疏松症的治疗作用。方法 6 9例绝经 <4年的妇女被随机分为 3组 (每组 2 3例 ) ,A组给予倍美力 0 .6 2 5mg +安宫黄体酮 2mg +钙尔奇D片 1g/d ;B组给予倍美力 0 .3mg +安宫黄体酮 2mg +钙尔奇D片 1g/d ;C组给予安慰剂 +钙尔奇D片 1g/d ;连续用药 2年。在用药前、用药后 6、12、2 4个月分别检测骨密度、骨代谢生化指标、骨细胞调节因子、子宫内膜增厚及乳房情况。结果 A组和B组在用药后一年骨密度有明显提高 ,而C组在一年后骨密度呈下降趋势。治疗组中均未发现子宫内膜的异常增生。骨代谢生化指标及血清IL 6水平在用药 6个月时就有显著下降。结论 在绝经早期的妇女中 ,小剂量雌激素加钙剂能防治骨质疏松症的发生 ,增加HRT(性激素替代疗法 )的安全性 ,降低子宫内膜过度增厚和阴道出血的发生率。此种雌激素加钙剂防治骨质疏松症的联合治疗方案值得推广。 相似文献
12.
目的 探讨老年性骨质疏松症的证候特征及其相关危险因素.方法 对98名老年性骨质疏松症患者进行中医证候评定,以39例骨密度正常老年人作对照,Logistic回归分析等统计学方法用于相关危险因素的分析.结果 老年性骨质疏松症最常出现的中医证候是气虚证、肾精亏虚证;较常出现的证候是瘀血证和痰浊证.气虚证是老年性骨质疏松症的独立危险因素;如果考虑两种病理因素合而为病,则肾精亏虚与阴虚是老年性骨质疏松症的危险因素,脾气虚与瘀血阻络两两交互作用,发生骨质疏松症的危险性更高.结论 骨密度与气虚证、脾虚血瘀证、肾虚阴亏证具有密切关系,气虚、肾虚阴亏、脾虚血瘀是老年性骨质疏松症的基本病理因素. 相似文献
13.
阿仑膦酸钠防治绝经后骨质疏松的疗效 总被引:1,自引:0,他引:1
目的观察国产阿仑膦酸钠防治绝经后骨质疏松症的疗效。方法56例50~74岁骨量减少或骨质疏松的绝经后妇女随机分为两组(每组28人),每日给予阿仑膦酸钠10mg/d或安慰剂,两组均加服碳酸钙片和维生素D,治疗6个月。试验前后用双能X线吸收法检测腰椎和髋部的骨矿密度(bonemineraldensity,BMD),同时检测骨转换的生化指标。结果与治疗前相比,治疗组腰椎BMD平均增加5%(P<0.01),对照组各部位的BMD均下降(P<0.05);治疗组骨吸收指标和骨形成指标均降低,其中NTx下降最明显,近75.7%(P<0.001),而对照组却无显著性变化。结论国产阿仑膦酸钠能降低绝经后妇女的骨转换,增加骨量。 相似文献
14.
With the aging of the population,the inci-dence of pri mary osteoporosis is getting higher andhigher,among which post menopausal osteoporosis(PMOP)is the most commontype.As an effectivemedicine to inhibit bone absorption,bisphospho-nates has become the main medicationtotreat oste-oporosis.In this clinical trial,we investigated theefficacy of residronate sodium,the third-generationbisphosphonates made in China,in the treat mentof PMOP by exploring its effect on bone mineraldensity(BMD)and b… 相似文献
15.
XU Xiao-juan SHEN Lin YANG Yan-ping LU Fu-rong ZHU Rui SHUAI Bo LI Cheng-gang WU Man-xiang 《中华医学杂志(英文版)》2013,126(13):2480-2484
Background Sclerostin, expressed exclusively by osteocytes, is a negative regulator of bone formation. To gain insights into the action of sclerostin in postmenopausal osteoporosis, we evaluated serum sclerostin levels in postmenopausal women and investigated its possible associations with bone turnover markers in patients with postmenopausal osteoporosis.
Methods We detected serum sclerostin, and measured lumbar spine bone mineral density in 650 Chinese postmenopausal women. We also assessed serum levels of β-isomerized C-terminal crosslinking of type I collagen, intact N-terminal propeptide of type I collagen, N-mid fragment of osteocalcin, 25-hydroxyvitamin D, and estradiol.
Results Serum sclerostin levels were lower in postmenopausal osteoporotic women compared with non-osteoporotic postmenopausal women ((38.79±7.43) vs. (52.86±6.69) pmol/L, P <0.001). Serum sclerostin was positively correlated with lumbar spine bone mineral density (r=0.391, P <0.001) and weakly negatively correlated with β-isomerized C-terminal crosslinking of type I collagen, intact N-terminal propeptide of type I collagen, N-mid fragment of osteocalcin (r= –0.225, P <0.001; r= –0.091, P=0.046; r= –0.108, P=0.018; respectively) in postmenopausal osteoporosis. There was no significant association of serum sclerostin with age, body mass index, 25-hydroxyvitamin D, and estradiol (r= –0.004, P=0.926; r=0.067, P=0.143; r=0.063, P=0.165; r= –0.045, P=0.324; respectively).
Conclusion Sclerostin may be involved in the pathogenesis of postmenopausal osteoporosis and may play a role in bone turnover.
相似文献
16.
目的 分析脑梗死患者并发骨质疏松的发生情况,探讨影响脑梗死患者骨质疏松的影响因素,为临床诊断和防治提供依据.方法 应用双能X线骨密度仪测定脑梗死组和对照组的骨密度,并对影响骨质疏松发生的因素进行相关性分析.结果 男性脑梗死怠者骨质疏松发生率为31.39%,女性为46.25%,女性患者发生率高于男性患者,差异有显著性(P<0.05).影响骨质疏松因素中,脑梗死病情程度和病程、女性、高龄、高血压病、吸烟、低体重指数是脑梗死患者骨质疏松发生的高危因素.结论 影响脑梗死患者骨质疏松发生的主要因素是脑梗死病情程度和病程,次要因素有年龄、性别、高血压病等.脑梗死患者易发生骨质疏松,骨质疏松以瘫痪侧肢体为重. 相似文献
17.
目的:探讨女性骨关节炎(OA)骨质疏松(OP)的危险因素。方法:使用双能X线骨密度仪测定300例女性OA患者(OA组)和101名健康女性(对照组)第1~4腰椎(L1~4)、股骨颈、全髋等部位骨密度(BMD)。统计分析各组与OP相关的危险因素。结果:女性OA患者OP发生率显著高于健康女性(P<0.01),各部位BMD均低于对照组(P<0.01)。OA患者OP组各部位BMD均明显低于非OP组(P<0.01),OA患者绝经后组各部位BMD均低于绝经前组(P<0.01),OA患者OP组较非OP组年龄更大,绝经时间更长,孕产次数更多(P<0.01)。OA组OP女性未来10年骨折的概率明显高于对照组(P<0.01)。结论:女性OA患者发生OP和骨折风险均显著高于健康女性,其OP的发生和多因素相关,增龄、绝经年限长、孕产次数多是OA患者发生OP的主要危险因素。 相似文献
18.
Effects of vibration therapy on bone mineral density in postmenopausal women with osteoporosis 总被引:2,自引:0,他引:2
Background Jaw osteonecrosis possibly associated with the administration of bisphosphonates is expected to be treated with a non-pharmacologic approach. This study aimed to determine whether noninvasive, mechanically mediated vibration would inhibit the decline in bone mineral density (BMD) that follows menopause, enhance the BMD of the lumbar and femoral neck, and reduce chronic back pain in postmenopausal women with osteoporosis.
Methods A total of 116 postmenopausal women with osteoporosis participated in this study, and they were divided into groups A (66 patients) and B (50). Group A received vibration treatment (Subjects vertically stand on the vibration platform, with a vibration frequency of 30 Hz, amplitude of 5 mm; they received the treatment five times per week, ten minutes each time and totally for six months), whereas women of group B served as controls without any treatment. L2-4 BMD, bilateral femoral neck BMD, and body mass index (BMI) were recorded before the treatment or at the third and sixth months of the treatment respectively. After the ending of the treatment, the change of BMD in each group was compared and analyzed. Chronic back pain was evaluated by visual analogue scale (VAS) at baseline and the third and sixth months of the treatment.
Results Of the 116 women, 94 including 51 women from group A ((61.23±8.20) years) and 43 women from group B ((63.73±5.45) years), completed the study. There were no significant differences in baseline characteristics including age, BMI, menopausal years, lumbar BMD, femoral neck BMD, and VAS between the two groups. The lumbar BMD of the 51 women in group A increased by 1.3% (P=0.034) after vibration treatment for 3 months and by 4.3% at the sixth month (P=0.000). The lumbar BMD in group B was decreased at the third month, but there was not statistical significance (P〉0.05) At the sixth month, it was decreased by 1.9% (P 〈0.05). The femoral neck BMD of the 51 women in group A was slightly in 相似文献
Methods A total of 116 postmenopausal women with osteoporosis participated in this study, and they were divided into groups A (66 patients) and B (50). Group A received vibration treatment (Subjects vertically stand on the vibration platform, with a vibration frequency of 30 Hz, amplitude of 5 mm; they received the treatment five times per week, ten minutes each time and totally for six months), whereas women of group B served as controls without any treatment. L2-4 BMD, bilateral femoral neck BMD, and body mass index (BMI) were recorded before the treatment or at the third and sixth months of the treatment respectively. After the ending of the treatment, the change of BMD in each group was compared and analyzed. Chronic back pain was evaluated by visual analogue scale (VAS) at baseline and the third and sixth months of the treatment.
Results Of the 116 women, 94 including 51 women from group A ((61.23±8.20) years) and 43 women from group B ((63.73±5.45) years), completed the study. There were no significant differences in baseline characteristics including age, BMI, menopausal years, lumbar BMD, femoral neck BMD, and VAS between the two groups. The lumbar BMD of the 51 women in group A increased by 1.3% (P=0.034) after vibration treatment for 3 months and by 4.3% at the sixth month (P=0.000). The lumbar BMD in group B was decreased at the third month, but there was not statistical significance (P〉0.05) At the sixth month, it was decreased by 1.9% (P 〈0.05). The femoral neck BMD of the 51 women in group A was slightly in 相似文献
19.
目的:探讨老年女性低骨密度值的相关因素,为老年女性骨质疏松的早期防治提供理论依据。方法:用双能X线吸收法(DEXA)测定915例第一汽车制造厂60~74岁退休女性职工尺桡骨的骨密度值,并对年龄,大米、杂粮、海产品、牛奶、酸奶、咖啡、豆浆、面、鸡蛋、水果的摄入量,是否吸烟,是否饮酒及绝经年数等进行问卷调查,同时测量身高、体质量。结果:年龄、是否经常摄入面、鸡蛋和水果、是否吸烟、绝经年数、体质指数(BMI)与骨密度值有关,差异有显著性(P<0.05);多重逐步回归分析显示:年龄与骨密度值呈负相关(B=-0.440,P<0.05),绝经年数与骨密度值呈负相关(B=-0.314,P<0.05),是否吸烟与骨密度值呈负相关(B=-0.650,P<0.05),BMI与骨密度值呈正相关(B=0.959,P<0.05)。结论:高龄、吸烟、绝经年数长、低BMI是60~74岁女性原发性骨质疏松的相关危险因素 。 相似文献